RT Journal Article
SR Electronic
T1 Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e020692
DO 10.1136/bmjopen-2017-020692
VO 8
IS 6
A1 Dorsey-Treviño, Edgar Gerardo
A1 Contreras-Garza, Belinda Maricela
A1 González-González, José Gerardo
A1 Álvarez-Villalobos, Neri
A1 Salcido-Montenegro, Alejandro
A1 Díaz González-Colmenero, Alejandro
A1 Farrell, Ann M
A1 González-Nava, Victoria
A1 Rodríguez-Tamez, Giselle
A1 Montori, Victor M
A1 Rodriguez-Gutierrez, René
YR 2018
UL http://bmjopen.bmj.com/content/8/6/e020692.abstract
AB Introduction Sodium glucose cotransporter 2 (SGLT-2) inhibitors are a relatively new drug-class of glucose-lowering medications. Several trials and systematic reviews have demonstrated their beneficial effect on some macrovascular outcomes. Their effect on microvascular outcomes has been reported as positive in several trials, however, their effect remains uncertain. Therefore, we report the protocol of a systematic review and meta-analysis aimed at determining the effect of SGLT-2 inhibitors regarding patient-important and surrogate microvascular outcomes in patients with type 2 diabetes.Methods and analysis A comprehensive search will be conducted to find eligible articles from each database’s earliest inception to November 2017. These databases will include Ovid, MEDLINE, EMBASE, Web of Science, and Scopus. We will search for randomized controlled trials (RCTs) that compare any of the SGLT-2 inhibitors with any other active treatment or placebo assessing microvascular outcomes in either their primary or secondary outcomes. Reviewers working independently and in duplicate will review all abstracts, and full-text manuscripts for eligibility, and will systematically extract the data and will assess the risk of bias in the included studies. Random-effects models will also be used.Ethics and dissemination The results of the systematic review will be disseminated via publication in a peer-reviewed journal regardless of outcome and will be presented at relevant conferences. The data we will use do not include individual patient data, so ethical approval is not requiredPROSPERO registration number CRD42017076460.